Portfolio AOP Health
Product overview with focus on integrated therapies for rare diseases and in critical care.
AOP Health's focus is on integrated therapies for rare diseases and in critical care. The portfolio comprises products in the following therapeutic areas: Hemato-oncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Critical Care. AOP Health’s strategic goal is to constantly deliver new treatment options with respect to rare diseases and critical care.
- United Arab Emirates
- Czech Republic
- United Kingdom
is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder.
Adepend is used as part of a comprehensive treatment programme against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
Motetis® is used as symptomatic therapy in the treatment of Huntington’s disease.
Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
Ospolot® is an antiepileptic drug and is used to treat Rolandic epilepsy.
Tetmodis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease.
Tetrabenazine is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease.
Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.